title: CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath.
authors.forename: Rowena D
authors.initials: RD
authors.lastname: Bainton
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Byrne
authors.forename: Barbara J
authors.initials: BJ
authors.lastname: Davy
authors.forename: Nigel H
authors.initials: NH
authors.lastname: Russell
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003586:Cytomegalovirus Infections / Q000139:chemically induced*; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014184:Transplantation, Homologous / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab